Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status

Breast Cancer Research

Steve Goodison²  Amber Rivard¹  Virginia Urquidi²  Jessica Wang-Rodriguez² 

[1] Department of Pathology, University of California, San Diego, La Jolla, California, USA;Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California, USA

关键词: quantitative PCR;    microdissection;    metastasis;    immunohistochemistry;    breast carcinoma;   

Others  :  1118798
DOI  :  10.1186/bcr620

 received in 2003-01-13, accepted in 2003-06-06,  发布年份 2003

【 摘 要 】

Background

Our previous characterization of a human breast tumor metastasis model identified several candidate metastasis genes. The expression of osteopontin (OPN) correlated with the metastatic phenotype, whereas thrombospondin-1 (TSP-1) and tyrosinase-related protein-1 (TYRP-1) correlated with the nonmetastatic phenotype of independent MDA-MB-435 cell lines implanted orthotopically into athymic mice. The aim of the present study was to examine the cellular distribution of these molecules in human breast tissue and to determine whether the relative expression level of these three genes is associated with human breast tumor metastasis.

Methods

Sixty-eight fresh, frozen specimens including 31 primary infiltrating ductal carcinomas, 22 nodal metastases, 10 fibroadenomas, and five normal breast tissues were evaluated for OPN expression, TSP-1 expression and TYRP-1 expression. Immunohistochemistry was performed to monitor the cellular distribution and to qualitatively assess expression. Quantitative analysis was achieved by enrichment of breast epithelial cells using laser-capture microdissection and subsequent real-time, quantitative PCR.

Results

The epithelial components of the breast tissue were the source of OPN and TSP-1 expression, whereas TYRP-1 was present in both the epithelial and stromal components. Both OPN and TSP-1 expression were significantly higher in malignant epithelial sources over normal and benign epithelial sources, but no difference in expression levels was evident between primary tumors with or without metastases, nor between primary and metastatic carcinomas.

Conclusion

Elevated expression of OPN and TSP-1 may play a role in the pathogenesis of breast cancer. The multiplex analysis of these molecules may enhance our ability to diagnose and/or prognosticate human breast malignancy.

【 授权许可】

   
2003 Wang-Rodriguez et al., licensee BioMed Central Ltd (Print ISSN 1465-5411; Online ISSN 1465-542X). This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK, Eds: [http://seer.cancer.gov/csr/1975_2000] webciteSEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute; 2003.
• [2]Urquidi V, Kawai K, Agarwal D, Woodman AC, Tarin D, Goodison S: Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 2002, 8:61-74.
• [3]Tuck A, Arsenault D, O'Malley F, Hota C, Ling M, Wilson S, Chambers A: Osteopontin indices increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246.
• [4]Lawler J: The functions of thrombospondin-1 and -2. Curr Opin Cell Biol 2000, 12:634-640.
• [5]Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V: Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an Isogenic Human Breast Cancer Model. Differentiation 2002, 71:114-125.
• [6]Denhardt D, Lopez C, Rollo E, Hwang S, An X, Walther S: Osteopontin-induced modifications of cellular functions. Ann NY Acad Sci 1995, 760:127-142.
• [7]Ding Q, Stewart JJ, Prince C, Chang P, Trikha M, Han X, Grammer J, Gladson C: Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 2002, 62:5336-5343.
• [8]Senger D, Perruzzi C, Gracey C, Papadopoulos A, Tenen D: Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 1988, 48:5770-5774.
• [9]Singhal H, Bautista D, Tonkin K, O'Malley F, Tuck A, Chambers AH, Harris JFR: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997, 3:605-611.
• [10]Bornstein P: Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995, 130:503-506.
• [11]Reiher F, Volpert O, Jimenex B, Crawford S, Dinney C, Henkin J, Haviv F, Bouck N, Campbell S: Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002, 98:682-689.
• [12]Gasparini G, Toi M, Biganzoli E, Dittadi R, Ranelli M, Morabito A, Boracchi P, Gion M: Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p52, cathepsin D, hormone receptors and prognosis. Oncology 2001, 60:72-80.
• [13]Tuck A, O'Malley F, Singhal H, Harris J, Tonkin K, Kerkvliet N, Saad Z, Doig G, Chambers A: Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998, 79:502-508.
• [14]Wang T, Albo D, Tuszynski G: Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery 2002, 132:220-225.
• [15]Brown L, Papadopoulous-Sergiou A, Berse B, Manseau E, Tognazzi K, Perruzzi C, Dvorak H, Senger D: Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994, 145:610-623.
• [16]Chen Y-T, Stockert E, Tsang S, Copland D, Old L: Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995, 93:8125-8129.
• [17]Elston EW, Ellis IO: Pathological prognostic factors in breast cancer. I The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
• [18]Simone N, Bonner R, Gillespie J, Emmert-Buck M, Liotta L: Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet 1998, 14:272-276.
• [19]Bautista D, Xuan J, Hota C, Chambers A, Harris J: Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994, 269:23280-23285.
• [20]Sung V, Gilles C, Murray A, Clarke R, Aaron A, Azumi N, Thompson E: The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp Cell Res 1998, 241:273-284.
• [21]Oates A, Barraclough R, Rudland P: The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996, 13:97-104.
• [22]Behrend E, Craig A, Wilson S, Denhardt D, Chambers A: Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994, 54:832-837.
• [23]Gardner H, Berse B, Senger D: Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 1994, 9:2321-2326.
• [24]Hirota S, Ito A, Nagoshi J, Takeda M, Kurata A, Takatsuka Y, Kohri K, Nomura S, Kitamura Y: Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab Invest 1995, 72:64-69.
• [25]Rudland P, Platt-Higgins A, El-Tanani M, Rudland S, Barraclough R, Winstanley J, Howit R, West C: Prognostic significance of the metastasis-associated protein Osteopontin in human breast cancer. Cancer Res 2002, 62:3417-3427.
• [26]Weinstat-Saslow D, Zabrenetzky V, VanHoutte K, Frazier W, Roberts D, Steeg P: Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994, 54:6504-6511.
• [27]Volpert O, Lawler J, Bouck N: A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA 1998, 95:6343-6348.
• [28]Tobita K, Kijima H, Dowaki S, Oida Y, Kashiwagi H, Ishii M, Sugio Y, Sekka T, Ohtani Y, Tanaka M, Inokuchi S, Makuuchi H: Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol 2002, 21:1189-1195.
• [29]Goddard J, Sutton C, Jones J, O'Byrne K, Kockelbergh R: Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer. Eur Urol 2002, 42:464-468.
• [30]Rice A, Steward M, Quinn C: Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast. J Clin Pathol 2002, 55:921-925.
• [31]Albo D, Shinohara T, Tuszynski G: Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res 1995, 108:51-60.
• [32]de Vries T, Trancikova D, Ruiter D, van Muijen G: High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer 1998, 78:1156-1161.
• [33]de Wit N, Burtscher H, Weidle U, Ruiter D, van Muijen G: Differentially expressed genes identified in human melanoma cell lines with different metastatic behavior using high density oligonucleotide arrays. Melanoma Res 2002, 12:57-69.
• [34]Fang D, Hallman J, Sangha N, Kute T, Hammarback J, White W, Setaluri V: Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma. Am J Pathol 2001, 158:2107-2115.
• [35]Rubin D, Rubin E: The possible role of tyrosinase in malignant growth. Met Hypotheses 1983, 10:469-471.